These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32418731)

  • 1. Incretin-based drugs and intestinal obstruction: A pharmacovigilance study.
    Gudin B; Ladhari C; Robin P; Laroche ML; Babai S; Hillaire-Buys D; Faillie JL
    Therapie; 2020; 75(6):641-647. PubMed ID: 32418731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
    Faillie JL; Babai S; Crépin S; Bres V; Laroche ML; Le Louet H; Petit P; Montastruc JL; Hillaire-Buys D;
    Acta Diabetol; 2014; 51(3):491-7. PubMed ID: 24352344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
    Willemen MJ; Mantel-Teeuwisse AK; Straus SM; Meyboom RH; Egberts TC; Leufkens HG
    Diabetes Care; 2011 Feb; 34(2):369-74. PubMed ID: 21270195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database.
    Ado Moumouni AN; Robin P; Hillaire-Buys D; Faillie JL
    Fundam Clin Pharmacol; 2018 Apr; 32(2):216-226. PubMed ID: 29144574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.
    Faillie JL; Yin H; Yu OHY; Herrero A; Altwegg R; Renoux C; Azoulay L
    Clin Pharmacol Ther; 2022 Jan; 111(1):272-282. PubMed ID: 34587280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysis of the vigibase®.
    Carnovale C; Mazhar F; Arzenton E; Moretti U; Pozzi M; Mosini G; Leoni O; Scatigna M; Clementi E; Radice S
    Expert Opin Drug Saf; 2019 Nov; 18(11):1099-1108. PubMed ID: 31519110
    [No Abstract]   [Full Text] [Related]  

  • 7. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
    Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
    BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
    Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
    Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database.
    Béné J; Moulis G; Bennani I; Auffret M; Coupe P; Babai S; Hillaire-Buys D; Micallef J; Gautier S;
    Br J Dermatol; 2016 Aug; 175(2):296-301. PubMed ID: 27031194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS).
    Huang J; Zhao Y; Cao Y; Zhang Q; Ran D; Li J; Luo L; Qiu F; Meng L
    Int J Clin Pharm; 2022 Aug; 44(4):993-1003. PubMed ID: 35776375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study.
    Ueda P; Wintzell V; Melbye M; Eliasson B; Söderling J; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Hviid A; Pasternak B
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1226-1237.e14. PubMed ID: 37716613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
    Jedlowski PM; Jedlowski MF; Fazel MT
    Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced disseminated intravascular coagulation: a pharmacovigilance study on World Health Organization's database.
    Bonaldo G; Vaccheri A; Melis M; Motola D
    J Thromb Thrombolysis; 2020 Nov; 50(4):763-771. PubMed ID: 32445062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
    Chen W; Cai P; Zou W; Fu Z
    Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®).
    Batteux B; Bennis Y; Bodeau S; Masmoudi K; Hurtel-Lemaire AS; Kamel S; Gras-Champel V; Liabeuf S
    Bone; 2021 Dec; 153():116137. PubMed ID: 34343739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between dipeptidyl peptidase-4 inhibitor and aspiration pneumonia: disproportionality analysis using the spontaneous reporting system in Japan.
    Noguchi Y; Esaki H; Murayama A; Sugioka M; Koyama A; Tachi T; Teramachi H
    Eur J Clin Pharmacol; 2020 Feb; 76(2):299-304. PubMed ID: 31822955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting.
    Tuccori M; Lapi F; Testi A; Coli D; Moretti U; Vannacci A; Motola D; Salvo F; Rivolta AL; Blandizzi C; Mugelli A; Del Tacca M
    Drug Saf; 2008; 31(12):1115-23. PubMed ID: 19026028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug induced stuttering: pharmacovigilance data.
    Trenque T; Morel A; Trenque A; Azzouz B
    Expert Opin Drug Saf; 2021 Mar; 20(3):373-378. PubMed ID: 33337944
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: Case reports and disproportionality analyses in Vigibase.
    Perino J; Mottal N; Bohbot Y; Servant V; Berroneau A; Poustis P; Fenaux P; Laribi K; Charbonnier A; Bilion E; Calmettes C; Bégaud B; Pigneux A; Milpied N; Miremont-Salamé G; Théophile H; Dimicoli-Salazar S
    Br J Clin Pharmacol; 2020 May; 86(5):991-998. PubMed ID: 31912911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.